Twist Bioscience (TWST) Capital Expenditures (2017 - 2026)

Twist Bioscience (TWST) has 10 years of Capital Expenditures data on file, last reported at -$4.4 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at -$4.4 million, down 449.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.2 million (up 649.88% YoY), and the FY2025 annual result was $28.0 million, up 451.69% from the prior year.
• Capital Expenditures eased to -$4.4 million in Q1 2026 per TWST's latest filing, from $10.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $40.6 million in Q2 2022 and troughed at -$24.6 million in Q3 2023.
• A 5-year average of $7.6 million and a median of $2.1 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures jumped 1376.48% in 2025, then slumped 449.44% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $11.8 million in 2022, then plunged by 87.26% to $1.5 million in 2023, then soared by 41.83% to $2.1 million in 2024, then jumped by 366.95% to $10.0 million in 2025, then tumbled by 144.46% to -$4.4 million in 2026.
• Business Quant data shows TWST's Capital Expenditures at -$4.4 million in Q1 2026, $10.0 million in Q4 2025, and $12.4 million in Q3 2025.